New antibody shows promise in early trial for advanced colon cancer
NCT ID NCT03017807
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This early-phase study tested a new antibody drug (anti-EGFr) in 18 people with advanced colorectal cancer that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received the drug weekly until their disease worsened or side effects became too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Kelun Pharmaceutical Co., Ltd.
Chengdu, China
Conditions
Explore the condition pages connected to this study.